ProCE Banner Activity

Phase II CAPTIVATE: First-line Ibrutinib + Venetoclax in Chronic Lymphocytic Leukemia (Interim Analysis)

Slideset Download
Conference Coverage
Early results show promising clinical responses and MRD clearance with combination first-line treatment in CLL with ibrutinib and venetoclax.

Released: June 06, 2018

Expiration: June 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen